7 results
Primary objectiveTo evaluate the relationship of incremental doses of NVA237 q.d. and b.i.d. and their effect on trough FEV1 after 28 days of treatment, as defined by the percentage of the maximal effect that each dose achieves in relation to the…
Primary objectivesTo confirm that NVA237 50µg o.d. (delivered via a SDDPI) vs. placebo significantly increases trough FEV1 (defined as mean evaluation at 23 h 15 min and 23 h 45 min post dose) following 12 weeks of treatment in patients with…
Primary objective: To demonstrate that QVA149 (110/50 *g o.d.) is superior to NVA237 (50 *g o.d.) with regard to the rate of moderate to severe COPD exacerbations during 64 weeks of treatmentSecondary objectives: To demonstrate that QVA149 (110/50 *…
To determine the added value of signs, symptoms and H-FABP measurement in in- or excluding acute coronary syndrome in patients with thoracic complaints in general practice
Primary objective: To demonstrate the superiority of QVA 110/50 µg compared to both QAB149 150 µg and NVA237 50 µg in terms of trough FEV1 (mean of 23 h 15 min and 23 h 45 min post-dose) following 26 weeks of treatment in patients with moderate to…
Our objectives in both adult and paediatric psoriasis patients are (I) To validate the Handheld LSCI Device for visualization of vascular changes within psoriatic plaques. (II) Identification of the most active and least active sides of psoriatic…
The aim of our project is to establish the feasibility, effectiveness, costs and acceptance of early case finding of CD in children attending the YHCCs in a well described region in the Netherlands, using a POC test for TG2A determination.…